ACAdrien Chauchet

Adrien Chauchet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adrien Chauchet has a total of 289 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)

    by Katell Le Dû, Adrien Chauchet, Sophie Sadot-Lebouvier, Olivier Fitoussi, Bijou Fontanet, Arnaud Saint-Lezer, Frédéric Maloisel, Cédric Rossi, Sylvain Carras, Anne Parcelier, et al.

    Background: Relapse is a major event in patients with lymphoma. Therefore, early detection may have an impact on quality of life and overall survival. Patient-reported outcome measures have demonstrated clinical benefits for patients with lung cancer; however, evidence is lacking in patients with lymphoma. We evaluated the effect of a web-mediated follow-up application for patients with lymphoma at high risk of relapse. Objective: This study aims to demonstrate that monitoring patients via a web application enables the detection of at least 30% more significant events occurring between 2 systematic follow-up consultations with the specialist using an electronic questionnaire. Methods: We conducted a prospective, randomized phase 3 trial comparing the impact of web-based follow-up (experimental arm) with a standard follow-up (control arm). The trial was based on a 2-step triangular test and was designed to have a power of 90% to detect a 30% improvement in the detection of significant events. A significant event was defined as a relapse, progression, or a serious adverse event. The study covered the follow-up period after completion of first-line treatment or relapse (24 months). Eligible patients were aged 18 years and older and had lymphoma at a high risk of relapse. In the experimental arm, patients received a 16-symptom questionnaire by email every 2 weeks. An email alert was sent to the medical team based on a predefined algorithm. The primary objective was assessed after the inclusion of the 40th patient. The study was continued for the duration of the analysis. Results: A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France, with 27 in the experimental arm and 25 in the control arm. The median follow-up was 21.3 (range 1.3‐25.6) months, and 121 events were reported during the study period. Most events occurred in the experimental arm (83/119, 69.7%) compared with 30.2% (36/119) in the control arm. A median number of 3.5 (range 1-8) events per patient occurred in the experimental arm, and 1.8 (range 1-6) occurred in the control arm (P=.01). Progression and infection were the most frequently reported events. Further, 19 patients relapsed during follow-up: 6 in the experimental arm and 13 in the control arm (P<.001), with a median follow-up of 7.7 (range 2.8‐20.6) months and 6.7 (range 1.9‐16.4) months (P=.94), respectively. Statistical analysis was conducted after including the 40th patient, which showed no superiority of the experimental arm over the control arm. The study was therefore stopped after the 52nd patient was enrolled. Conclusions: The primary objective was not reached; however, patient-reported outcome measures remain essential for detecting adverse events in patients with cancer, and the electronic monitoring method needs to demonstrate its effectiveness and comply with international safety guidelines.


  • Open Access

    Randomized trial comparing a web-based follow-up with routine surveillance in high-risk lymphoma: results of the phase 3 Sentinel Lymphoma trial. (Preprint)

    by Katell Le Dû Sr, Adrien Chauchet Sr, Sophie Sadot-Lebouvier Sr, Olivier Fitoussi Sr, Bijou Fontanet Sr, Arnaud Saint-Lezer Sr, Frédéric Maloisel Sr, Cédric Rossi Sr, Sylvain Carras Sr, Anne Parcelier Sr, et al.

    BACKGROUND Relapse is a major event for lymphoma patients. Early detection could have an impact on quality of life and overall survival. Patient-related outcome measures have already demonstrated clinical benefit for lung cancer patients. Evidence is lacking for lymphoma patients. We proposed to evaluate the impact of a web-application follow-up for lymphoma patients at high risk of relapse. OBJECTIVE The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. METHODS We planned a prospective, randomized phase 3 trial, comparing web-based follow-up (experimental arm) to a standard arm (control arm). Eligible patients were 18 years of age and older with lymphoma at high risk of relapse. Patients could have T-cell lymphoma in first partial or complete response, Hodgkin lymphoma in second partial or complete response, or diffuse large B-cell lymphoma in first partial or complete response with a revised high IPI score (≥3) or in second partial or complete response. The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. An interim analysis was performed at the inclusion of the first 40 patients. RESULTS A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France: 27 in the experimental arm and 25 in the control arm. Median follow-up was 21.3 months (range, [1.3-25.6] months). One hundred and twenty-one events were reported during the study period. Most events were reported in the experimental arm (83/119, 69.7%) compared to 30.2% (36/119) in the control arm, with a mean number of events per patient of 3.5 in the experimental arm and 1.8 in the control arm (p=.0041). Progression and infection were most frequently reported events. Nineteen patients relapsed during follow-up: 6 in the experimental arm and 13 in the standard arm (p<.001), with a median follow-up of 7.7 (range, [2.8-20.6] months) and 6.7 (range [1.9-16.4] months) (p=.94) respectively. Nine out of 26 patients (34.6%) in the experimental group did not receive their electronic questionnaire and the supplier was unable to remedy this. The interim analysis showed that there was no difference in the diagnosis of events. CONCLUSIONS PRO measures remain essential, but the electronic monitoring method must comply with international safety guidelines. CLINICALTRIAL ClinicalTrials.gov NCT 03154710

  • Open Access

    Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM)

    by Marion Detroit, Mathis Collier, Nathanaël Beeker, Lise Willems, Justine Decroocq, Bénédicte Deau-Fischer, Marguerite Vignon, Rudy Birsen, Frederique Moufle, Clément Leclaire, et al.

    Immunotherapy (IT) is a major therapeutic strategy for lymphoma, significantly improving patient prognosis. IT remains ineffective for a significant number of patients, however, and exposes them to specific toxicities. The identification predictive factors around efficacy and toxicity would allow better targeting of patients with a higher ratio of benefit to risk. PRONOSTIM is a multicenter and retrospective study using the Clinical Data Warehouse (CDW) of the Greater Paris University Hospitals network. Adult patients with Hodgkin lymphoma or diffuse large-cell B lymphoma treated with immune checkpoint inhibitors or CAR T (Chimeric antigen receptor T) cells between 2017 and 2022 were included. Analysis of covariates influencing progression-free survival (PFS) or the occurrence of grade ≥3 toxicity was performed. In total, 249 patients were included. From this study, already known predictors for response or toxicity of CAR T cells such as age, elevated lactate dehydrogenase, and elevated C-Reactive Protein at the time of infusion were confirmed. In addition, male gender, low hemoglobin, and hypo- or hyperkalemia were demonstrated to be potential predictive factors for progression after CAR T cell therapy. These findings prove the attractiveness of CDW in generating real-world data, and show its essential contribution to identifying new predictors for decision support before starting IT.


  • Top Cited Papers
    Open Access

    COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

    by Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolai Klimko, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, et al.

    Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.


  • Open Access

    Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study

    by Marion Lam, Valérie Touitou, Sylvain Choquet, Nathalie Cassoux, Hervé Ghesquières, Laurent Kodjikian, Anna Schmitt, Sarra Gattoussi, Émeline Tabouret, Magali Sampo, et al.

    The treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high‐dose methotrexate (IV HD‐MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first‐line treatment with HD‐MTX between 2011 and 2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL‐10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL‐10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow‐up of 61 months, 42/59 (71%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression‐free survival, ocular‐free survival and brain‐free survival were 75, 18, 29 and 73 months, respectively. IV HD‐MTX based systemic therapy as a first‐line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL‐10.


  • Open Access

    Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies

    by Julien Magne, Alizée Jenvrin, Adrien Chauchet, Olivier Casasnovas, Anne Donzel, Laurence Jego, Bernard Aral, Julien Guy, Nathalie Nadal, Dewi Vernerey, et al.

    Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and contributes, in conjunction with immunoglobulin variable heavy chain gene mutation status, to the identification of two forms of this disease. The aim of this report was firstly, to design an easy and suitable RT-qPCR method to quantify SOX11 mRNA expression in mantle cell lymphoma and other B cell malignancies with the proper reference gene; secondly, to define the best threshold of relative quantity of SOX11 mRNA in order to reach the best compromise between sensitivity and specificity. For best discrimination of MCL and non-MCL groups we determined an area under the curve (AUC) of 0.9750 and a threshold of 1.76 with 100% sensitivity and 88% specificity. AUC and threshold values of respectively 0.91/1.346 [87% sensitivity, 80% specificity] and 0.9525/1.7120 [100% sensitivity, 88% specificity] for GAPDH and RPLP0 respectively denote that the RPLP0 reference gene alone is sufficient for PCR housekeeping gene. This work describes an RT-qPCR assay for SOX11 expression in order to better characterize MCL at diagnosis. Further studies on larger cohorts are needed to evaluate this molecular tool, especially for the follow-up of minimal residual disease.